Regencell Bioscience Holdings Ltd (RGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) has a cash flow conversion efficiency ratio of -2.125x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.59 Million) by net assets ($1.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Regencell Bioscience Holdings Ltd worth for the company's overall valuation and market capitalisation.
Regencell Bioscience Holdings Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Regencell Bioscience Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regencell Bioscience Holdings Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Regencell Bioscience Holdings Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Siriuspoint Ltd
NYSE:SPNT
|
-0.012x |
|
Chongqing Brewery Co Ltd
SHG:600132
|
-0.387x |
|
Empresas CMPC
SN:CMPC
|
0.007x |
|
MINISO GRP HLD.ADS/4
F:MIF
|
N/A |
|
Atlanta Braves Holdings, Inc. Series C Common Stock
NASDAQ:BATRK
|
0.042x |
|
Shandong Dongyue Organosilicon Mat
SHE:300821
|
-0.009x |
|
FB Financial Corp
NYSE:FBK
|
0.039x |
|
Ningbo Boway Alloy Material Co Ltd
SHG:601137
|
-0.056x |
Annual Cash Flow Conversion Efficiency for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Regencell Bioscience Holdings Ltd from 2003 to 2025. View Regencell Bioscience Holdings Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $4.86 Million | $-3.11 Million | -0.641x | -31.57% |
| 2024-06-30 | $8.22 Million | $-4.00 Million | -0.487x | -17.62% |
| 2023-06-30 | $11.99 Million | $-4.96 Million | -0.414x | -34.24% |
| 2022-06-30 | $17.08 Million | $-5.27 Million | -0.308x | -260.65% |
| 2021-06-30 | $-4.00 Million | $-767.31K | 0.192x | -29.97% |
| 2020-06-30 | $-2.65 Million | $-726.57K | 0.274x | +28.88% |
| 2019-06-30 | $-1.84 Million | $-390.99K | 0.213x | +144.40% |
| 2018-06-30 | $-855.80 Million | $409.90 Million | -0.479x | +2.12% |
| 2017-06-30 | $-838.90 Million | $410.50 Million | -0.489x | +1.14% |
| 2016-06-30 | $-877.60 Million | $434.40 Million | -0.495x | -26.87% |
| 2015-06-30 | $-894.80 Million | $349.10 Million | -0.390x | +19.77% |
| 2014-06-30 | $-713.40 Million | $346.90 Million | -0.486x | +2.24% |
| 2013-06-30 | $-696.80 Million | $346.60 Million | -0.497x | +19.58% |
| 2012-06-30 | $-570.90 Million | $353.10 Million | -0.618x | -16.90% |
| 2011-06-30 | $-490.30 Million | $259.40 Million | -0.529x | +68.20% |
| 2010-06-30 | $-246.90 Million | $410.80 Million | -1.664x | -49.13% |
| 2009-06-30 | $-242.00 Million | $270.00 Million | -1.116x | +83.40% |
| 2008-06-30 | $-119.00 Million | $800.00 Million | -6.723x | +53.56% |
| 2007-06-30 | $-21.00 Million | $304.00 Million | -14.476x | -216.26% |
| 2006-06-30 | $31.00 Million | $386.00 Million | 12.452x | +128.44% |
| 2005-06-30 | $71.00 Million | $387.00 Million | 5.451x | +813.79% |
| 2004-06-30 | $798.00 Million | $476.00 Million | 0.596x | +103.73% |
| 2003-06-30 | $1.27 Billion | $373.00 Million | 0.293x | -- |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more